Pyxis Oncology (NASDAQ:PYXS) Trading Up 1.5%

Pyxis Oncology, Inc. (NASDAQ:PYXSGet Rating)’s stock price was up 1.5% on Thursday . The company traded as high as $2.75 and last traded at $2.72. Approximately 24,774 shares were traded during trading, a decline of 84% from the average daily volume of 154,089 shares. The stock had previously closed at $2.68.

Pyxis Oncology Trading Up 2.6 %

The stock’s 50-day moving average is $2.56 and its two-hundred day moving average is $4.15.

Pyxis Oncology (NASDAQ:PYXSGet Rating) last issued its quarterly earnings results on Friday, May 13th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.35). As a group, analysts expect that Pyxis Oncology, Inc. will post -3.13 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pyxis Oncology

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PYXS. Perceptive Advisors LLC acquired a new stake in shares of Pyxis Oncology in the 4th quarter valued at $21,326,000. Citadel Advisors LLC acquired a new stake in shares of Pyxis Oncology in the 4th quarter valued at $16,482,000. Laurion Capital Management LP acquired a new stake in shares of Pyxis Oncology in the 4th quarter valued at $12,751,000. Hhlr Advisors LTD. acquired a new stake in shares of Pyxis Oncology in the 4th quarter valued at $8,386,000. Finally, Tekla Capital Management LLC raised its holdings in shares of Pyxis Oncology by 424.7% in the 1st quarter. Tekla Capital Management LLC now owns 708,303 shares of the company’s stock valued at $2,630,000 after purchasing an additional 573,303 shares in the last quarter. Hedge funds and other institutional investors own 61.30% of the company’s stock.

Pyxis Oncology Company Profile

(Get Rating)

Pyxis Oncology, Inc, a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors.

Featured Articles

Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.